Jubilant Pharmova quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	2,229	1,901	+17.3%
EBITDA	248	290	−14.4%
EBITDA margin	11.1%	15.2%	−4.1 pts
Profit before tax	86.4	155	−44.1%
Net profit	56.4	103	−45.0%
EPS	₹3.57	₹6.49	−45.0%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	2,229	2,290	2,123	1,966	1,901	1,929	1,822	1,752	1,732	1,759	1,677	1,680	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	19.9	23.7	20.5	9.8	12.0	11.9	9.2	21.7	14.0	14.4	35.8	9.9
	2,249	2,314	2,143	1,976	1,913	1,941	1,831	1,774	1,746	1,773	1,713	1,690
	638	643	592	565	521	584	467	469	465	497	432	464
	86.9	84.5	82.0	73.6	73.0	84.8	81.2	69.3	61.8	53.9	71.8	58.4
	23.5	−14.0	42.2	−42.0	24.7	−42.7	26.2	16.5	34.6	−23.8	32.6	34.5
	754	767	706	636	591	591	560	564	553	555	582	532
	54.2	56.5	56.1	50.2	49.0	52.7	55.6	61.0	71.0	73.0	71.3	66.1
	127	117	121	105	98.1	95.2	91.3	91.4	90.7	101	94.6	96.6
	479	471	410	392	402	367	400	344	366	405	342	349
	2,163	2,124	2,010	1,780	1,758	1,731	1,681	1,615	1,642	1,661	1,625	1,601
	248	339	290	341	290	345	287	289	252	271	218	242
	121	223	169	237	192	250	196	198	161	170	123	145
Profit
	86.4	190	133	196	155	209	150	159	104	112	87.9	89.0
	0.0	−13.7	−39.7	−5.8	0.0	−3.3	−18.9	−14.2	396	−169	0.0	0.0
	86.4	176	93.5	190	155	206	131	145	500	−57.1	87.9	89.0
	29.6	65.5	21.6	36.1	37.5	115	32.3	40.0	26.1	108	45.1	35.1
	0.4	−8.8	16.0	34.3	14.4	−60.1	−2.5	1.9	−8.2	−100	−10.5	0.8
	30.0	56.7	37.6	70.4	51.9	54.7	29.8	41.9	17.9	8.1	34.6	35.9
	0.0	0.0	−0.1	−0.1	−0.1	−0.1	−0.3	−0.1	0.0	3.4	13.1	9.0
	56.4	119	55.8	120	103	151	101	103	482	−61.8	66.4	62.1
	56.4	119	55.9	120	103	151	101	103	482	−65.2	53.3	53.1
	−19.1	282	62.4	160	41.1	−4.6	63.5	30.0	−3.9	−6.6	17.0	34.2
	37.3	401	118	280	144	147	164	133	478	−68.4	83.4	96.3
	56.5	119	55.9	120	103	154	101	103	482	−58.6	66.8	62.5
	−0.1	−0.1	−0.1	−0.4	−0.4	−2.3	−0.2	−0.3	−0.3	−3.2	−0.4	−0.4
Per share
	₹3.57	₹7.55	₹3.52	₹7.59	₹6.49	₹9.71	₹6.37	₹6.47	₹30.44	−₹3.69	₹4.22	₹3.94
	₹3.56	₹7.52	₹3.52	₹7.57	₹6.47	₹9.68	₹6.36	₹6.46	₹30.35	−₹3.68	₹4.20	₹3.94
Other comprehensive income — detail
	−19.1	282	62.4	160	41.1	−4.6	—	—	—	—	—	—
	0.1	7.7	0.4	−1.3	−0.4	0.8	−0.3	−0.4	−0.4	2.2	−0.7	−0.7
	0.0	0.4	0.1	−0.5	−0.1	−0.4	—	—	—	—	—	—
	—	—	—	—	—	—	−0.1	−0.2	−0.1	1.8	−0.3	−0.2
	−19.2	—	62.1	161	41.4	−5.8	—	30.2	−3.6	−7.0	17.4	34.7
	0.0	−275	0.0	0.0	0.0	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	−63.7	0.0	0.0	0.0	0.0	0.0
	37.4	401	118	281	144	149	165	133	478	−65.1	83.8	96.8
	−0.1	−0.2	0.1	−1.0	−0.5	−2.2	−0.6	−0.3	−0.3	−3.3	−0.4	−0.5
Per share — as-filed variants
	₹3.57	₹7.55	₹3.52	₹7.59	₹6.49	₹9.71	₹6.37	₹6.47	₹30.44	−₹3.69	₹4.22	₹3.94
	₹3.56	₹7.52	₹3.52	₹7.57	₹6.47	₹9.68	₹6.36	₹6.46	₹30.35	−₹3.68	₹4.20	₹3.94
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,481	1,577	1,406	1,370	1,283	1,303	1,247	1,198	1,170	1,231	1,141	1,123
	66.4%	68.9%	66.3%	69.7%	67.5%	67.5%	68.5%	68.3%	67.6%	70.0%	68.0%	66.8%
Adjusted (ex-exceptional items) — derived
	86.4	190	133	196	155	209	150	159	104	112	87.9	89.0
	0.0	−13.7	−39.7	−5.8	0.0	−3.3	−18.9	−14.2	396	−169	0.0	0.0
	56.4	129	79.5	124	103	154	115	113	100	107	66.4	62.1
	₹3.57	₹8.14	₹5.02	₹7.82	₹6.49	₹9.87	₹7.29	₹7.11	₹6.32	₹6.39	₹4.22	₹3.94

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JUBLPHARMA₹946.00

Jubilant Pharmova Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersGLAND PPLPHARMA KIMS INDGN ONESOURCE GRANULES PFIZER POLYMEDMcap ₹14,947 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,680.3	1,677.1	1,758.6	1,731.7	1,752.3	1,821.7	1,928.8	1,900.7	1,966.4	2,122.5	2,290.0	2,229.4
Other Income	9.9	35.8	14.4	14.0	21.7	9.2	11.9	12.0	9.8	20.5	23.7	19.9
Total Income	1,690.2	1,712.9	1,773.0	1,745.7	1,774.0	1,830.9	1,940.7	1,912.7	1,976.2	2,143.0	2,313.7	2,249.3
Expenses
+ Cost of Materials Consumed	464.4	431.5	497.3	465.3	469.0	467.0	584.0	520.5	564.9	592.1	642.8	638.3
+ Purchases of Stock-in-Trade	58.4	71.8	53.9	61.8	69.3	81.2	84.8	73.0	73.6	82.0	84.5	86.9
+ Changes in Inventories	34.5	32.6	-23.8	34.6	16.5	26.2	-42.7	24.7	-42.0	42.2	-14.0	23.5
+ Employee Benefit Expense	531.8	581.5	555.0	552.9	564.3	560.1	590.6	591.1	636.2	706.4	766.9	753.5
+ Finance Costs	66.1	71.3	73.0	71.0	61.0	55.6	52.7	49.0	50.2	56.1	56.5	54.2
+ Depreciation & Amortisation	96.6	94.6	101.0	90.7	91.4	91.3	95.2	98.1	104.8	120.7	116.8	127.3
+ Other Expenses	349.4	341.7	404.8	365.6	343.8	399.8	366.7	401.8	392.3	410.3	470.5	479.2
Total Expenses	1,601.2	1,625.0	1,661.2	1,641.9	1,615.3	1,681.2	1,731.3	1,758.2	1,780.0	2,009.8	2,124.0	2,162.9
EBITDA	241.8	218.0	271.4	251.5	289.4	287.4	345.4	289.6	341.4	289.5	339.3	248.0
EBIT	145.2	123.4	170.4	160.8	198.0	196.1	250.2	191.5	236.6	168.8	222.5	120.7
Profit
PBT before Exceptional Items	89.0	87.9	111.8	103.8	158.7	149.7	209.4	154.5	196.2	133.2	189.7	86.4
+ Exceptional Items	0.0	0.0	-168.9	395.9	-14.2	-18.9	-3.3	0.0	-5.8	-39.7	-13.7	0.0
Pretax Income	89.0	87.9	-57.1	499.7	144.5	130.8	206.1	154.5	190.4	93.5	176.0	86.4
+ Current Tax	35.1	45.1	108.1	26.1	40.0	32.3	114.8	37.5	36.1	21.6	65.5	29.6
+ Deferred Tax	0.8	-10.5	-100.0	-8.2	1.9	-2.5	-60.1	14.4	34.3	16.0	-8.8	0.4
Tax Expense	35.9	34.6	8.1	17.9	41.9	29.8	54.7	51.9	70.4	37.6	56.7	30.0
+ Share of Associates & JVs	9.0	13.1	3.4	0.0	-0.1	-0.3	-0.1	-0.1	-0.1	-0.1	0.0	0.0
Net Income	62.1	66.4	-61.8	481.8	102.5	100.7	151.3	102.5	119.9	55.8	119.3	56.4
+ Net Income — Continuing Ops	53.1	53.3	-65.2	481.8	102.6	101.0	151.4	102.6	120.0	55.9	119.3	56.4
+ Other Comprehensive Income	34.2	17.0	-6.6	-3.9	30.0	63.5	-4.6	41.1	160.4	62.4	281.9	-19.1
Total Comprehensive Income	96.3	83.4	-68.4	477.9	132.5	164.2	146.7	143.6	280.3	118.2	401.2	37.3
Net Income to Common	62.5	66.8	-58.6	482.1	102.8	100.9	153.6	102.9	120.3	55.9	119.4	56.5
Minority Interest	-0.4	-0.4	-3.2	-0.3	-0.3	-0.2	-2.3	-0.4	-0.4	-0.1	-0.1	-0.1
Per Share
Basic EPS	3.94	4.22	-3.69	30.44	6.47	6.37	9.71	6.49	7.59	3.52	7.55	3.57
Diluted EPS	3.94	4.20	-3.68	30.35	6.46	6.36	9.68	6.47	7.57	3.52	7.52	3.56
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-4.6	41.1	160.4	62.4	281.9	-19.1
+ Items NOT to be Reclassified to P&L	-0.7	-0.7	2.2	-0.4	-0.4	-0.3	0.8	-0.4	-1.3	0.4	7.7	0.1
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.4	-0.1	-0.5	0.1	0.4	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.2	-0.3	1.8	-0.1	-0.2	-0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	34.7	17.4	-7.0	-3.6	30.2	—	-5.8	41.4	161.2	62.1	—	-19.2
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.0	0.0	-274.6	0.0
+ Tax on Items to be Reclassified — alt tag	0.0	0.0	0.0	0.0	0.0	-63.7	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	96.8	83.8	-65.1	478.2	132.8	164.8	148.9	144.1	281.3	118.1	401.4	37.4
Comprehensive Income — Non-controlling Interests	-0.5	-0.4	-3.3	-0.3	-0.3	-0.6	-2.2	-0.5	-1.0	0.1	-0.2	-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.94	4.22	-3.69	30.44	6.47	6.37	9.71	6.49	7.59	3.52	7.55	3.57
Diluted EPS — Continuing Operations	3.94	4.20	-3.68	30.35	6.46	6.36	9.68	6.47	7.57	3.52	7.52	3.56
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,123.0	1,141.2	1,231.2	1,170.0	1,197.5	1,247.3	1,302.7	1,282.5	1,369.9	1,406.2	1,576.7	1,480.7
Gross Margin %	66.83	68.05	70.01	67.56	68.34	68.47	67.54	67.48	69.67	66.25	68.85	66.42
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	89.0	87.9	111.8	103.8	158.7	149.7	209.4	154.5	196.2	133.2	189.7	86.4
− Exceptional Items (reconciliation)	0.0	0.0	-168.9	395.9	-14.2	-18.9	-3.3	0.0	-5.8	-39.7	-13.7	0.0
Net Income Adj (tax-effected)	62.1	66.4	107.1	100.1	112.6	115.3	153.7	102.5	123.6	79.5	128.6	56.4
EPS Adj	3.94	4.22	6.39	6.32	7.11	7.29	9.87	6.49	7.82	5.02	8.14	3.57
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Jubilant Pharmova quarterly results

Jubilant Pharmova (NSE: JUBLPHARMA) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹56.5 crore, down 45.1% from ₹103 crore in Q1 FY26 and down 52.7% from ₹119 crore in Q4 FY26. Revenue from operations was ₹2,229 crore, up 17.3% year on year and down 2.6% from the previous quarter.

Q2 FY26 results (a year earlier): 31 October 2025
Q1 FY27 results (the latest): 10 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹56.5 Cr−45.1% vs Q1 FY26−52.7% vs Q4 FY26
Q1 FY27 revenue: ₹2,229 Cr+17.3% vs Q1 FY26−2.6% vs Q4 FY26
Q1 FY27 operating margin: 5.4%−4.7 pts vs Q1 FY26−4.3 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹120 CrRevenue ₹1,966 Cr
Q1 FY27 EPS (basic): ₹3.57

Questions

When will Jubilant Pharmova announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 31 October 2025.

What were Jubilant Pharmova's Q1 FY27 results?

Consolidated net profit was ₹56.5 crore, down 45.1% from ₹103 crore in Q1 FY26 and down 52.7% from ₹119 crore in Q4 FY26. Revenue from operations was ₹2,229 crore, up 17.3% year on year and down 2.6% from the previous quarter.

What was Jubilant Pharmova's net profit in FY26?

Consolidated net profit was ₹399 crore in FY26 (April 2025–March 2026), down 52.5% from ₹839 crore in FY25. It was a profit of ₹77.1 crore in FY24 and a loss of ₹61 crore in FY23.

What will Jubilant Pharmova's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹120 crore and revenue from operations ₹1,966 crore. The latest quarter, Q1 FY27, had a net profit of ₹56.5 crore and revenue of ₹2,229 crore.

How has Jubilant Pharmova's profit changed over the last four quarters?

Net profit by quarter: ₹120 crore in Q2 FY26, ₹55.9 crore in Q3 FY26, ₹119 crore in Q4 FY26 and ₹56.5 crore in Q1 FY27. That is ₹352 crore over the four quarters, down 23.5% from ₹460 crore in the four quarters before. Revenue from operations: ₹1,966 crore, ₹2,123 crore, ₹2,290 crore and ₹2,229 crore.

What was Jubilant Pharmova's revenue in FY26?

Revenue from operations was ₹8,280 crore in FY26 (April 2025–March 2026), up 14.4% from ₹7,235 crore in FY25. It was ₹6,703 crore in FY24 and ₹6,282 crore in FY23: up 31.8% over three years, 9.6% a year on average.

Where do these Jubilant Pharmova figures come from?

From Jubilant Pharmova's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.